<DOC>
	<DOCNO>NCT00585416</DOCNO>
	<brief_summary>The purpose research determine effectiveness CGC-11047 subject metastatic hormone refractory prostate cancer measure change PSA .</brief_summary>
	<brief_title>Study CGC-11047 Patients With Metastatic Hormone Refractory Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Metastatic hormone refractory prostate cancer . Eastern Cooperative Oncology Group ( ECOG ) Performance status 01. testosterone &lt; 50ng/dL . Patients must continue primary androgen deprivation LHRH analogue undergone orchiectomy . Progressive disease androgen deprivation . Patients whose clinical condition would make chemotherapy clearly indicate . Patients receive systemic chemotherapy treatment metastatic disease . Peripheral neuropathy &gt; Grade 1 Prior antiangiogenic therapy , include thalidomide . Patients inadequate recovery prior surgical procedure , patient undergo major surgical procedure radiation within 4 week prior study entry . Patients receive radiopharmaceutical ( strontium , samarium ) within 8 week prior enrollment . Patients know brain metastasis history brain metastasis . History stroke within 6 month treatment significant neurological limitation . Patients receive 2 prior investigational treatment . Uncontrolled intercurrent illness Patients history myocardial infarction within prior 6 month , hospitalization decompensated congestive heart failure within prior 6 month , history significant / symptomatic cardiac arrhythmia</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>Hormone Refractory</keyword>
	<keyword>Metastatic</keyword>
</DOC>